Lexicon presents six posters on LX4211 at ADA meeting

Download PDF Copy

Editorial Checklist

Reviewed

Lexicon Pharmaceuticals, Inc.Jun 10 2012

NewsGuard 100/100 Score

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will present six posters summarizing the mechanism of action and safety of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) currently in mid-stage development for type 2 diabetes, at the 72nd Scientific Sessions of the American Diabetes Association (ADA) in Philadelphia, Pennsylvania during the Saturday morning poster session on June 9, 2012.

Lexicon has completed dosing in a Phase 2b study of LX4211 in 299 patients with type 2 diabetes and expects to report top-line results at the end of June.

Source:

Lexicon Pharmaceuticals, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: Arthritis, Carcinoid Syndrome, Diabetes, Endocrinology, Gene, Glaucoma, Glucose, Irritable Bowel Syndrome, Pharmaceuticals, Rheumatoid Arthritis, Type 1 Diabetes, Type 2 Diabetes, Type I Diabetes

Comments (0)

Download PDF Copy

Suggested Reading

Global gap in diabetes prevalence and treatment has widened since 1990

Global gap in diabetes prevalence and treatment has widened since 1990

Diabetes rates skyrocket globally with millions left untreated

Diabetes rates skyrocket globally with millions left untreated

Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options

Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options

Spermidine regulates RIPK1 to combat diabetes and vascular damage

Spermidine regulates RIPK1 to combat diabetes and vascular damage

Tirzepatide significantly reduces weight and diabetes risk in patients with obesity and prediabetes

Tirzepatide significantly reduces weight and diabetes risk in patients with obesity and prediabetes

SGLT2 inhibitor canagliflozin shown to improve kidney oxygenation in diabetes patients

SGLT2 inhibitor canagliflozin shown to improve kidney oxygenation in diabetes patients

Comparing camel, cow, and goat milk: Which is best for diabetes and heart health?

Comparing camel, cow, and goat milk: Which is best for diabetes and heart health?

Diabetes medication shows promise in reducing alcohol use

Diabetes medication shows promise in reducing alcohol use

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Intensive blood pressure treatment reduces cardiovascular risk in people with Type 2 diabetes